GLP-1 수용체 작용제 시장 기회 및 전략(-2035년)

GLP-1 receptor agonist are a class of medications that mimic the action of the natural hormone glucagon-like peptide-1 (GLP-1), which helps regulate blood sugar levels. These drugs enhance insulin secretion, reduce glucagon production, slow gastric emptying and promote satiety. The primary purpose of GLP-1 receptor agonist is to improve blood glucose control and support weight reduction in patients with type 2 diabetes or obesity.

The GLP-1 receptor agonist market consists of sales, by entities (organizations, sole traders, or partnerships), of products and services related to GLP-1 receptor agonist, that gained approval for use in individuals with obesity, including those without diabetes, to assist in achieving and maintaining weight loss, especially in cases where traditional lifestyle interventions have been ineffective.

The global GLP-1 receptor agonist market was valued at $13,661.7 million in 2020 which grew till 2025 at a compound annual growth rate (CAGR) of more than 37.00%.

Increased Diagnosis Rates Of Metabolic Disorders

During the historic period, the GLP-1 receptor agonist market was mainly driven by the increased diagnosis rates of metabolic disorders. As screening initiatives expanded and health systems strengthened their capacity to detect conditions such as diabetes earlier, the number of individuals entering clinical management pathways grew substantially. For instance, in 2022, according to a study published in The Lancet Gastroenterology & Hepatology, a peer-reviewed medical journal focused on research and clinical advances in gastroenterology, hepatology and gastrointestinal surgery, the prevalence of non-alcoholic fatty liver disease (NAFLD) was 32%. The overall incidence reached 46.9 cases per 1,000 person-years, rising to 70.8 in men and 29.6 in women. Therefore, the GLP-1 receptor agonist market was mainly driven by the increased diagnosis rates of metabolic disorders.

Development Of Oral GLP-1 Candidates To Expand Patient Convenience And Treatment Accessibility

Major companies in the GLP-1 receptor agonist market are focusing on the development of oral GLP-1 formulations designed to address rising global demand for more convenient, non-injectable metabolic therapies. These innovations aim to improve treatment adherence, reduce reliance on injectable delivery systems and broaden therapeutic accessibility for individuals managing obesity and type 2 diabetes. For instance, in April 2025, Pfizer, a US-based pharmaceutical company specializing in metabolic and cardiometabolic drug development, provided an update on its oral GLP-1 receptor agonist candidate, danuglipron, following the completion of once-daily formulation studies intended to improve dosing convenience for patients. While the candidate achieved pharmacokinetic objectives, the program was discontinued due to a single case of potential liver injury among over 1,400 trial participants. This update underscores both the promise and the complexity of advancing oral GLP-1 drug technology, highlighting ongoing industry efforts to balance innovation, safety and patient-centric design as companies work to meet evolving global treatment needs.

The global GLP-1 receptor agonist market is highly concentrated, with large players operating in the market. The top seven competitors in the market made up 93.89% of the total market in 2024.

GLP-1 Receptor Agonist Global Market Opportunities And Strategies To 2035 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global GLP-1 receptor agonist market as it emerges from the COVID-19 shut down.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market research findings.
• Benchmark performance against key competitors.
• Utilize the relationships between key data sets for superior strategizing.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.

Where is the largest and fastest-growing market for GLP-1 receptor agonist? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The GLP-1 receptor agonist market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider GLP-1 receptor agonist market; and compares it with other markets.

The report covers the following chapters

• Introduction And Market Characteristics Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by drug class, by route of administration and by end users.
• Key Trends Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
• Growth Analysis And Strategic Analysis Framework Analysis on PESTEL, end use industries, market growth rate, global historic (2020-2025) and forecast (2025-2030, 2035F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
• Regional And Country Analysis Historic (2020-2025) and forecast (2025-2030, 2035F) market values and growth and market share comparison by region and country.
• Market Segmentation Contains the market values (2020-2025) (2025-2030, 2035F) and analysis for each segment by drug class, by route of administration and by end users in the market. Historic (2020-2025) and forecast (2025-2030) and (2030-2035) market values and growth and market share comparison by region market.
• Regional Market Size And Growth Regional market size (2025), historic (2020-2025) and forecast (2025-2030, 2035F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
• Competitive Landscape Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
• Other Major And Innovative Companies Details on the company profiles of other major and innovative companies in the market.
• Competitive Benchmarking Briefs on the financials comparison between major players in the market.
• Competitive Dashboard Briefs on competitive dashboard of major players.
• Key Mergers And Acquisitions Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
• Recent Developments Information on recent developments in the market covered in the report.
• Market Opportunities And Strategies Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
• Conclusions And Recommendations This section includes recommendations for GLP-1 receptor agonist providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
• Appendix This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report

Markets Covered:

• 1) By Drug Class: Liraglutide; Semaglutide; Tirzepatide; Dulaglutide; Other Drugs
• 2) By Route Of Administration: Parenteral; Oral
• 3) By End Users: Hospitals; Surgical Clinics; Other Users
• Companies Mentioned: Novo Nordisk AS; Eli Lilly Company; AstraZeneca Inc.; Sanofi SA; Glenmark Pharmaceuticals Limited.
• Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time-series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; GLP-1 receptor agonist indicators comparison.
• Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Table of Contents

1 Executive Summary

• 1.1 GLP-1 Receptor Agonist - Market Attractiveness And Macro Economic Landscape

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

• 6.1 General Market Definition
• 6.2 Summary
• 6.3 GLP-1 Receptor Agonist Market Definition And Segmentations
• 6.4 Market Segmentation By Drug Class
  • 6.4.1 Liraglutide
  • 6.4.2 Semaglutide
  • 6.4.3 Tirzepatide
  • 6.4.4 Dulaglutide
  • 6.4.5 Other Drugs
• 6.5 Market Segmentation By Route Of Administration
  • 6.5.1 Parenteral
  • 6.5.2 Oral
• 6.6 Market Segmentation By End Users
  • 6.6.1 Hospitals
  • 6.6.2 Surgical Clinics
  • 6.6.3 Other Users

7 Major Market Trends

• 7.1 Development Of Oral GLP-1 Candidates To Expand Patient Convenience And Treatment Accessibility
• 7.2 Integration Of Dual GLP-1/GIP Agonist To Enhance Weight-Loss Efficacy In Obesity Treatment
• 7.3 Launch Of Dual GLP-1/Glucagon Agonist To Address Metabolic Liver Disease Needs

8 Global GLP-1 Receptor Agonist Growth Analysis And Strategic Analysis Framework

• 8.1 Global GLP-1 Receptor Agonist Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • 8.1.1 Political
  • 8.1.2 Economic
  • 8.1.3 Social
  • 8.1.4 Technological
  • 8.1.5 Environmental
  • 8.1.6 Legal
• 8.2 Analysis Of End User (B2B And B2C)
  • 8.2.1 Hospital
  • 8.2.2 Surgical Clinics
  • 8.2.3 Other Users
• 8.3 Global GLP-1 Receptor Agonist Market Growth Rate Analysis
• 8.4 Historic Market Growth, 2020 - 2025, Value ($ Million)
  • 8.4.1 Market Drivers 2020 - 2025
  • 8.4.2 Market Restraints 2020 - 2025
• 8.5 Forecast Market Growth, 2025 - 2030, 2035F Value ($ Million)
• 8.6 Forecast Growth Contributors/Factors
  • 8.6.1 Quantitative Growth Contributors
  • 8.6.2 Drivers
  • 8.6.3 Restraints
• 8.7 Global GLP-1 Receptor Agonist Total Addressable Market (TAM)
  • 8.7.1 TAM Comparison Analysis

9 Global GLP-1 Receptor Agonist Market Segmentation

• 9.1 Global GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 9.2 Global GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 9.3 Global GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 9.4 Global GLP-1 Receptor Agonist Market, Sub-Segmentation Of Liraglutide, By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 9.5 Global GLP-1 Receptor Agonist Market, Sub-Segmentation Of Semaglutide, By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 9.6 Global GLP-1 Receptor Agonist Market, Sub-Segmentation Of Tirzepatide, By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 9.7 Global GLP-1 Receptor Agonist Market, Sub-Segmentation Of Dulaglutide, By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 9.8 Global GLP-1 Receptor Agonist Market, Sub-Segmentation Of Other Drugs, By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

10 GLP-1 Receptor Agonist Market, Regional and Country Analysis

• 10.1 Global GLP-1 Receptor Agonist Market, By Region, Historic and Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 10.2 Global GLP-1 Receptor Agonist Market, By Country, Historic and Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

11 Asia-Pacific Market

• 11.1 Summary
• 11.2 Market Overview
  • 11.2.1 Region Information
  • 11.2.2 Market Information
  • 11.2.3 Background Information
  • 11.2.4 Government Initiatives
  • 11.2.5 Regulations
  • 11.2.6 Regulatory Bodies
  • 11.2.7 Major Associations
  • 11.2.8 Taxes Levied
  • 11.2.9 Corporate Tax Structure
  • 11.2.10 Investments
  • 11.2.11 Major Companies
• 11.3 Asia-Pacific GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 11.4 Asia-Pacific GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 11.5 Asia-Pacific GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 11.6 China Market
• 11.7 Summary
• 11.8 Market Overview
  • 11.8.1 Country Information
  • 11.8.2 Market Information
  • 11.8.3 Background Information
  • 11.8.4 Government Initiatives
  • 11.8.5 Regulations
  • 11.8.6 Regulatory Bodies
  • 11.8.7 Major Associations
  • 11.8.8 Taxes Levied
  • 11.8.9 Corporate Tax Structure
  • 11.8.10 Investments
  • 11.8.11 Major Companies
• 11.9 China GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 11.10 China GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 11.11 China GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 11.12 India Market
• 11.13 India GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 11.14 India GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 11.15 India GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 11.16 Japan Market
• 11.17 Summary
• 11.18 Market Overview
  • 11.18.1 Country Information
  • 11.18.2 Market Information
  • 11.18.3 Background Information
  • 11.18.4 Government Initiatives
  • 11.18.5 Regulations
  • 11.18.6 Regulatory Bodies
  • 11.18.7 Major Associations
  • 11.18.8 Taxes Levied
  • 11.18.9 Corporate Tax Structure
  • 11.18.10 Investments
  • 11.18.11 Major Companies
• 11.19 Japan GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 11.20 Japan GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 11.21 Japan GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 11.22 Australia Market
• 11.23 Australia GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 11.24 Australia GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 11.25 Australia GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 11.26 Indonesia Market
• 11.27 Indonesia GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 11.28 Indonesia GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 11.29 Indonesia GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 11.30 South Korea Market
• 11.31 Summary
• 11.32 Market Overview
  • 11.32.1 Country Information
  • 11.32.2 Market Information
  • 11.32.3 Background Information
  • 11.32.4 Government Initiatives
  • 11.32.5 Regulations
  • 11.32.6 Regulatory Bodies
  • 11.32.7 Major Associations
  • 11.32.8 Taxes Levied
  • 11.32.9 Corporate Tax Structure
  • 11.32.10 Investments
  • 11.32.11 Major Companies
• 11.33 South Korea GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 11.34 South Korea GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 11.35 South Korea GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

12 Western Europe Market

• 12.1 Summary
• 12.2 Market Overview
  • 12.2.1 Region Information
  • 12.2.2 Market Information
  • 12.2.3 Background Information
  • 12.2.4 Government Initiatives
  • 12.2.5 Regulations
  • 12.2.6 Regulatory Bodies
  • 12.2.7 Major Associations
  • 12.2.8 Taxes Levied
  • 12.2.9 Corporate tax structure
  • 12.2.10 Investments
  • 12.2.11 Major Companies
• 12.3 Western Europe GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 12.4 Western Europe GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 12.5 Western Europe GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 12.6 Western Europe GLP-1 Receptor Agonist Market: Country Analysis
• 12.7 UK Market
• 12.8 UK GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 12.9 UK GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 12.10 UK GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 12.11 Germany Market
• 12.12 Germany GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 12.13 Germany GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 12.14 Germany GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 12.15 France Market
• 12.16 France GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 12.17 France GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 12.18 France GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 12.19 Italy Market
• 12.20 Italy GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 12.21 Italy GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 12.22 Italy GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 12.23 Spain Market
• 12.24 Spain GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 12.25 Spain GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 12.26 Spain GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

13 Eastern Europe Market

• 13.1 Summary
• 13.2 Market Overview
  • 13.2.1 Region Information
  • 13.2.2 Market Information
  • 13.2.3 Background Information
  • 13.2.4 Government Initiatives
  • 13.2.5 Regulations
  • 13.2.6 Regulatory Bodies
  • 13.2.7 Major Associations
  • 13.2.8 Taxes Levied
  • 13.2.9 Corporate Tax Structure
  • 13.2.10 Investments
  • 13.2.11 Major companies
• 13.3 Eastern Europe GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 13.4 Eastern Europe GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 13.5 Eastern Europe GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 13.6 Eastern Europe GLP-1 Receptor Agonist Market: Country Analysis
• 13.7 Russia Market
• 13.8 Russia GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 13.9 Russia GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 13.10 Russia GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

14 North America Market

• 14.1 Summary
• 14.2 Market Overview
  • 14.2.1 Region Information
  • 14.2.2 Market Information
  • 14.2.3 Background Information
  • 14.2.4 Government Initiatives
  • 14.2.5 Regulations
  • 14.2.6 Regulatory Bodies
  • 14.2.7 Major Associations
  • 14.2.8 Taxes Levied
  • 14.2.9 Corporate Tax Structure
  • 14.2.10 Investments
  • 14.2.11 Major Companies
• 14.3 North America GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 14.4 North America GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 14.5 North America GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 14.6 North America GLP-1 Receptor Agonist Market: Country Analysis
• 14.7 USA Market
• 14.8 Summary
• 14.9 Market Overview
  • 14.9.1 Country Information
  • 14.9.2 Market Information
  • 14.9.3 Background Information
  • 14.9.4 Government Initiatives
  • 14.9.5 Regulations
  • 14.9.6 Regulatory Bodies
  • 14.9.7 Major Associations
  • 14.9.8 Taxes Levied
  • 14.9.9 Corporate Tax Structure
  • 14.9.10 Investments
  • 14.9.11 Major Companies
• 14.10 USA GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 14.11 USA GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 14.12 USA GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 14.13 Canada Market
• 14.14 Summary
• 14.15 Market Overview
  • 14.15.1 Country Information
  • 14.15.2 Market Information
  • 14.15.3 Background Information
  • 14.15.4 Government Initiatives
  • 14.15.5 Regulations
  • 14.15.6 Regulatory Bodies
  • 14.15.7 Major Associations
  • 14.15.8 Taxes Levied
  • 14.15.9 Corporate Tax Structure
  • 14.15.10 Investments
  • 14.15.11 Major Companies
• 14.16 Canada GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 14.17 Canada GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 14.18 Canada GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

15 South America Market

• 15.1 Summary
• 15.2 Market Overview
  • 15.2.1 Region Information
  • 15.2.2 Market Information
  • 15.2.3 Background Information
  • 15.2.4 Government Initiatives
  • 15.2.5 Regulations
  • 15.2.6 Regulatory Bodies
  • 15.2.7 Major Associations
  • 15.2.8 Taxes Levied
  • 15.2.9 Corporate Tax Structure
  • 15.2.10 Investments
  • 15.2.11 Major Companies
• 15.3 South America GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 15.4 South America GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 15.5 South America GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 15.6 South America GLP-1 Receptor Agonist Market: Country Analysis
• 15.7 Brazil Market
• 15.8 Brazil GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 15.9 Brazil GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 15.10 Brazil GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

16 Middle East Market

• 16.1 Summary
• 16.2 Market Overview
  • 16.2.1 Region Information
  • 16.2.2 Market Information
  • 16.2.3 Background Information
  • 16.2.4 Government Initiatives
  • 16.2.5 Regulations
  • 16.2.6 Regulatory Bodies
  • 16.2.7 Major Associations
  • 16.2.8 Taxes Levied
  • 16.2.9 Corporate Tax Structure
  • 16.2.10 Investments
  • 16.2.11 Major Companies
• 16.3 Middle East GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 16.4 Middle East GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 16.5 Middle East GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

17 Africa Market

• 17.1 Summary
• 17.2 Market Overview
  • 17.2.1 Region Information
  • 17.2.2 Market Information
  • 17.2.3 Background Information
  • 17.2.4 Government Initiatives
  • 17.2.5 Regulations
  • 17.2.6 Regulatory Bodies
  • 17.2.7 Major Associations
  • 17.2.8 Taxes Levied
  • 17.2.9 Corporate Tax Structure
  • 17.2.10 Investments
  • 17.2.11 Major Companies
• 17.3 Africa GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 17.4 Africa GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
• 17.5 Africa GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

18 Competitive Landscape And Company Profiles

• 18.1 Company Profiles
• 18.2 Novo Nordisk AS
  • 18.2.1 Company Overview
  • 18.2.2 Products And Services
  • 18.2.3 Financial Overview
• 18.3 Eli Lilly Company
  • 18.3.1 Company Overview
  • 18.3.2 Products And Services
  • 18.3.3 Business Strategy
  • 18.3.4 Financial Overview
• 18.4 AstraZeneca Inc.
  • 18.4.1 Company Overview
  • 18.4.2 Products And Services
  • 18.4.3 Financial Overview
• 18.5 Sanofi SA
  • 18.5.1 Company Overview
  • 18.5.2 Products And Services
  • 18.5.3 Financial Overview
• 18.6 Glenmark Pharmaceuticals Limited
  • 18.6.1 Company Overview
  • 18.6.2 Products And Services
  • 18.6.3 Financial Overview

19 Other Major And Innovative Companies

• 19.1 Teva Pharmaceutical Industries Ltd.
  • 19.1.1 Company Overview
  • 19.1.2 Products And Services
• 19.2 Amneal Pharmaceuticals
  • 19.2.1 Company Overview
  • 19.2.2 Products And Services
• 19.3 Innovent Biologics Inc.
  • 19.3.1 Company Overview
  • 19.3.2 Products And Services
• 19.4 Boehringer Ingelheim International GmbH
  • 19.4.1 Company Overview
  • 19.4.2 Products And Services
• 19.5 Hanmi Pharm Co. Ltd.
  • 19.5.1 Company Overview
  • 19.5.2 Products And Services
• 19.6 Amgen Inc.
  • 19.6.1 Company Overview
  • 19.6.2 Products And Services
• 19.7 Sun Pharmaceutical Industries Ltd.
  • 19.7.1 Company Overview
  • 19.7.2 Products And Services
• 19.8 Jiangsu Hengrui Medicine Co.
  • 19.8.1 Company Overview
  • 19.8.2 Products And Services
• 19.9 Zealand Pharma A/S
  • 19.9.1 Company Overview
  • 19.9.2 Products And Services
• 19.10 Dong-A ST Co. Ltd.
  • 19.10.1 Company Overview
  • 19.10.2 Products And Services
• 19.11 Novartis AG
  • 19.11.1 Company Overview
  • 19.11.2 Products And Services
• 19.12 Hansoh Pharma
  • 19.12.1 Company Overview
  • 19.12.2 Products And Services
• 19.13 Structure Therapeutics Inc.
  • 19.13.1 Company Overview
  • 19.13.2 Products And Services
• 19.14 Viking Therapeutics
  • 19.14.1 Company Overview
  • 19.14.2 Products And Services
• 19.15 Altimmune
  • 19.15.1 Company Overview
  • 19.15.2 Products And Services

20 Competitive Benchmarking

21 Competitive Dashboard

22 Key Mergers And Acquisitions

• 22.1 Pfizer Acquired Metsera
• 22.2 Roche Acquired Carmot

23 Recent Developments In GLP-1 Receptor Agonist

• 23.1 Advancement Of Small-Molecule Oral GLP-1 Therapies To Improve Accessibility And Ease Of Use

24 Opportunities And Strategies

• 24.1 Global GLP-1 Receptor Agonist Market In 2030 - Countries Offering Most New Opportunities
• 24.2 Global GLP-1 Receptor Agonist Market In 2030 - Segments Offering Most New Opportunities
• 24.3 Global GLP-1 Receptor Agonist Market In 2030 - Growth Strategies
  • 24.3.1 Market Trend Based Strategies
  • 24.3.2 Competitor Strategies

25 GLP-1 Receptor Agonist Market, Conclusions And Recommendations

• 25.1 Conclusions
• 25.2 Recommendations
  • 25.2.1 Product
  • 25.2.2 Place
  • 25.2.3 Price
  • 25.2.4 Promotion
  • 25.2.5 People

26 Appendix

• 26.1 Geographies Covered
• 26.2 Market Data Sources
• 26.3 Research Methodology
• 26.4 Currencies
• 26.5 The Business Research Company
• 26.6 Copyright and Disclaimer